Is performing lobectomy after the use of bevacizumab for a lung tumor dangerous?

Recent new drugs, such as bevacizumab (Bev), also result in a remarkable response. However, the safety of major lung resection after the use of Bev remains controversial. Is it really dangerous to perform major lung resection after the use of Bev for a lung tumor? In this report, we describe two pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Uramoto, Hidetaka, Nakajima, Yuki, Kinoshita, Hiroyasu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843098/
https://www.ncbi.nlm.nih.gov/pubmed/27158486
http://dx.doi.org/10.1016/j.amsu.2016.01.081
_version_ 1782428630882713600
author Uramoto, Hidetaka
Nakajima, Yuki
Kinoshita, Hiroyasu
author_facet Uramoto, Hidetaka
Nakajima, Yuki
Kinoshita, Hiroyasu
author_sort Uramoto, Hidetaka
collection PubMed
description Recent new drugs, such as bevacizumab (Bev), also result in a remarkable response. However, the safety of major lung resection after the use of Bev remains controversial. Is it really dangerous to perform major lung resection after the use of Bev for a lung tumor? In this report, we describe two patients who underwent surgery safely without fragile pathological findings of the vessels.
format Online
Article
Text
id pubmed-4843098
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-48430982016-05-06 Is performing lobectomy after the use of bevacizumab for a lung tumor dangerous? Uramoto, Hidetaka Nakajima, Yuki Kinoshita, Hiroyasu Ann Med Surg (Lond) Case Report Recent new drugs, such as bevacizumab (Bev), also result in a remarkable response. However, the safety of major lung resection after the use of Bev remains controversial. Is it really dangerous to perform major lung resection after the use of Bev for a lung tumor? In this report, we describe two patients who underwent surgery safely without fragile pathological findings of the vessels. Elsevier 2016-01-27 /pmc/articles/PMC4843098/ /pubmed/27158486 http://dx.doi.org/10.1016/j.amsu.2016.01.081 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Uramoto, Hidetaka
Nakajima, Yuki
Kinoshita, Hiroyasu
Is performing lobectomy after the use of bevacizumab for a lung tumor dangerous?
title Is performing lobectomy after the use of bevacizumab for a lung tumor dangerous?
title_full Is performing lobectomy after the use of bevacizumab for a lung tumor dangerous?
title_fullStr Is performing lobectomy after the use of bevacizumab for a lung tumor dangerous?
title_full_unstemmed Is performing lobectomy after the use of bevacizumab for a lung tumor dangerous?
title_short Is performing lobectomy after the use of bevacizumab for a lung tumor dangerous?
title_sort is performing lobectomy after the use of bevacizumab for a lung tumor dangerous?
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843098/
https://www.ncbi.nlm.nih.gov/pubmed/27158486
http://dx.doi.org/10.1016/j.amsu.2016.01.081
work_keys_str_mv AT uramotohidetaka isperforminglobectomyaftertheuseofbevacizumabforalungtumordangerous
AT nakajimayuki isperforminglobectomyaftertheuseofbevacizumabforalungtumordangerous
AT kinoshitahiroyasu isperforminglobectomyaftertheuseofbevacizumabforalungtumordangerous

Ejemplares similares